New Tool Allows View of Cell Division in 3D Models

Allen Institute | May 22, 2019

The Allen Institute for Cell Science recently launched the Integrated Mitotic Stem Cell, a new tool that visualizes mitosis. Mitosis is cell division in the typical human stem cell. It’s how a cell splits into two, duplicating all its genetic information and cellular components. The Integrated Mitotic Stem Cell merges images of 15 separate cellular components, creating a 3-dimensional map of what a human cell looks like during different steps in cell division. The idea is that it can assist researchers in better understanding how the separate stages and different components of the cell work together it’s also visually beautiful and entertaining, which makes it a valuable educational tool.

Spotlight

Biotherapeutics include innovative products for the treatment of chronic diseases such as cancer, diabetes, and rheumatoid arthritis, as well as for acute conditions such as myocardial infarction and stroke—and have two common denominators: biological origin and structural complexity.

Spotlight

Biotherapeutics include innovative products for the treatment of chronic diseases such as cancer, diabetes, and rheumatoid arthritis, as well as for acute conditions such as myocardial infarction and stroke—and have two common denominators: biological origin and structural complexity.

Related News

MEDICAL

Controlant now Providing Monitoring and Supply Chain Visibility for Pfizer-BioNTech COVID-19 Vaccine's Global Distribution

Controlant | December 16, 2020

Controlant, an leader in real-time supply chain monitoring and perceivability technologies for vigorously controlled ventures, for example, pharmaceuticals and life sciences and food and drink areas, today reported it is giving observing and Supply Chain Visibility administrations to Pfizer, comparable to the conveyance of Pfizer's mRNA-based Pfizer-BioNTech COVID-19 vaccine's worldwide circulation. In addition to the visibility and monitoring arrangements that Controlant is providing to Pfizer to mRNA-based Pfizer-BioNTech COVID-19 vaccine distribution supply chain, the organization is likewise working straightforwardly with the U.S. Government and wellbeing authorities, for example, the Center for Disease Control (CDC), U.S. Division of Health and Human Services (HHS), and stakeholders in Operation Warp Speed, to give nearby observing at U.S. Government-preferred designated vaccination areas to help consistently guarantee coherence during hand-off, actionable communication, and visibility, all through the entirety of the U.S. supply chain journey of the vaccines.

Read More

Stemcyte Submitted its Application for A Biologics License (BLA) For Its Product "HPC-Cord Blood" To The US FDA

Stemcyte | March 23, 2022

On January 7th, 2022, the FDA received the BLA (Biologics License Application) for the "HPC-Cord Blood" product. On March 8th, 2022, StemCyte was formally informed that the submission was acceptable to join the biologics license quality review process. The "HPC-Cord Blood" is an umbilical cord blood hematopoietic stem cell product intended for unrelated donor hematopoietic progenitor cell transplantation procedures in patients with hematopoietic system disorders an appropriate preparative regimen for hematopoietic and immunologic reconstitution. There have been over 40,000 successful umbilical cord blood transplants globally to treat disorders of the hematological and immunological systems and genetic metabolic diseases since the first successful use of umbilical cord blood to treat Fanconi Anemia patients in 1988. StemCyte has donated more than 2,200 cord blood units for transplantation to 1 in every 20 patients with umbilical cord blood transplants globally during the last 20 years. In addition, at least 350 transplant centers around the world, including well-known medical centers such as UCLA Medical Center, Duke University Hospital, Taiwan Chang Gung Memorial Hospital, and National Taiwan University Hospital, consistently meet the quality standards of international accrediting bodies and are recognized and trusted as safe and effective by StemCyte's products.

Read More

CELL AND GENE THERAPY

EXUMA Biotech Completes Series B2 to Advance Novel Cell & Gene Therapies

EXUMA Biotech Corp. | December 22, 2021

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and continued clinical investigation of its Tumor Metabolism Regulated CAR technology targeting solid tumors. New investors in the Series B2 financing included Americo Life, Inc., in addition to existing investors. "We are pleased to expand our investor base with support from this strategic group of investors who recognize the potential of our technologies to translate into life-changing therapies for cancer patients," Gregory Frost, Ph.D., EXUMA Biotech Chairman and Chief Executive Offer "Dr. Holmes is a renowned cancer specialist who will make an outstanding addition to our board of directors. He has dedicated his life to researching advanced cellular and immunotherapy treatments for hematologic malignancies and to the education of the oncology community about these new modalities," said Frost. Houston Holmes, M.D., received a BS in medical microbiology from Stanford University School of Medicine, an MD from the University of Texas Southwestern Medical School, and an MBA from the University of Texas at Dallas. He completed an internship and residency in internal medicine at Baylor University Medical Center, and fellowship in medical oncology/hematology at the National Cancer Institute/National Heart, Lung, and Blood Institute. Dr. Holmes has been in practice for over 20 years. "It's an exciting time for cell and gene therapies. I'm thrilled to be a part of EXUMA and to join the company in its mission to advance innovative therapies towards the clinic and for cancer patients in urgent need of new treatments," said Houston Holmes, M.D. About EXUMA Biotech EXUMA Biotech is a clinical-stage biotechnology company pioneering the discovery and development of novel cellular therapies and gene delivery solutions for patients with cancer. The company leverages its global R&D footprint to discover, manufacture and develop gene delivery platforms and gene programs that may overcome the safety, efficacy, and scalability challenges of cellular therapies in solid tumor and hematologic malignancies. The company is headquartered in West Palm Beach.

Read More